【24h】

Long-term outcomes of clinically significant vascular rings associated with congenital tracheal stenosis.

机译:与先天性气管狭窄相关的具有临床意义的重要血管环的长期结果。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: Congenital tracheal stenosis (CTS) associated with vascular rings (VRs) is considered a secondary condition, but relative indications for selective VRs or combined VR and CTS repairs are unclear. Here, we report long-term outcomes after VR repair associated with tracheal narrowing (TN). METHOD: Retrospective analysis of patients admitted to a single institution with VR from 1982 to 2004. Of 131 patients with VR (Cardiac Registry Database), 29 (19 males, 10 females; age range, 0 days-4 years) associated with symptomatic TN. Patients were followed until age 18 years. RESULTS: One hundred thirty-one patients with VR were categorized into 3 treatment groups. There were 102 patients with VR with no symptomatic TN treated by VR repair (4 deaths, 4% mortality). Of the 29 patients with VR + TN symptoms, 16 were treated by selective VR repair (mean age, 5.3 months; range, 17-288 days) with 3 deaths (19% mortality) and 13 underwent combined VR and CTS repairs (mean age, 11 months; range, 1 day-4 years) with6 deaths (46% mortality), for an overall mortality of 31% (P < .01, chi2 test). Of the 102 patients with VR, 17 had intracardiac anomalies with 3 deaths (18% mortality). In contrast, 7 of 29 patients with VR with TN and intracardiac anomalies died (57% mortality); 3 patients in combined cardiac and CTS repairs (2 deaths, 67% mortality) and 4 in selective VR repairs (2 deaths, 50% mortality). CONCLUSIONS: Not all cases of TN associated with VR require combined repairs. The presence of TN and/or intracardiac anomalies in patients with VR, however, increases mortality risk to the repair of VR. Surgical decision requires individualized clinical pathway.
机译:目的:与血管环(VR)相关的先天性气管狭窄(CTS)被认为是继发性疾病,但尚不清楚选择性VR或VR和CTS联合修复的相对适应症。在这里,我们报告VR修复后与气管狭窄(TN)相关的长期结果。方法:回顾性分析从1982年至2004年进入单一机构接受VR治疗的患者。在131例VR患者(心脏登记数据库)中,有29例(男性19例,女性10例;年龄在0天至4岁)与TN有关。随访患者直至18岁。结果:131例VR患者被分为3个治疗组。有102例无症状TN的VR患者接受了VR修复治疗(4例死亡,4%死亡率)。在29例具有VR + TN症状的患者中,有16例接受了选择性VR修复治疗(平均年龄5.3个月;范围17-288天),其中3例死亡(19%死亡率),其中13例接受了VR和CTS联合修复(平均年龄) ,11个月;范围为1天至4年,其中6例死亡(46%死亡率),总死亡率为31%(P <.01,chi2检验)。在102例VR患者中,有17例发生心内畸形,其中3例死亡(18%的死亡率)。相比之下,在29例具有TN和心内异常的VR患者中,有7例死亡(57%的死亡率)。 3例合并心脏和CTS修复的患者(2例死亡,死亡率67%)和4例选择性VR修复(2例死亡,50%死亡率)。结论:并非所有与VR相关的TN病例都需要联合修复。然而,VR患者中TN和/或心内异常的存在增加了VR修复的死亡风险。手术决策需要个性化的临床途径。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号